# PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers

> **NCT01205321** · PHASE1 · COMPLETED · sponsor: **Life Molecular Imaging SA** · enrollment: 19 (actual)

## Conditions studied

- Diagnostic Imaging

## Interventions

- **DRUG:** Bombesin (68Ga) labeled (BAY86-7548)
- **DRUG:** Bombesin (68Ga) labeled (BAY86-7548)

## Key facts

- **NCT ID:** NCT01205321
- **Lead sponsor:** Life Molecular Imaging SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2013-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01205321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01205321, "PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01205321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*